Doug Brunk is a San Diego-based award-winning reporter who began covering health care in 1991. Before joining the company, he wrote for the health sciences division of Columbia University and was an associate editor at Contemporary Long Term Care magazine when it won a Jesse H. Neal Award. His work has been syndicated by the Los Angeles Times and he is the author of two books related to the University of Kentucky Wildcats men's basketball program. Doug has a master’s degree in magazine journalism from the S.I. Newhouse School of Public Communications at Syracuse University. Follow him on Twitter @dougbrunk.
News
Common outcome measures for AD lack adequate reporting of race, skin tone
Of 165 studies analyzed, only 55 (33%) reported the distribution of race or ethnicity, while 5 (3%) reported the distribution of skin tone.
News
Genetic testing for neurofibromatosis 1: An imperfect science
“If you fulfill diagnostic criteria for NF1, the main reasons for doing genetic testing are, one, if the family wants to know that information,...
News
Autoinflammatory diseases ‘not so rare after all,’ expert says
“Dermatologists are in a unique position because they will often be the first specialist to see these patients and therefore make the diagnosis...
News
Expert proposes rethinking the classification of SJS/TEN
“After leaving the hospital, people with SJS or people with TEN need to have ongoing care, consultation, and explanation so they and their...
News
Pediatric alopecia areata in the U.S. has increased twofold since 2009, study finds
Analysis across race/ethnicity revealed significantly increased rates among children from minority backgrounds when compared with white children...
News
Proposed classification framework for atopic dermatitis unveiled
“There are some patients who have milder-looking lesions, but their itch is just out of control. ... This is a pattern that we need to recognize...
News
Nadolol bests propranolol for infantile hemangioma treatment out to 52 weeks
Kaplan-Meir analysis showed that patients in the propranolol group responded slower to treatment (P = .019), while safety data was...
News
Study eyes impact of isotretinoin on triglycerides, other lab measures
“Clinicians must weigh the laboratory values with the costs of laboratory testing, including opportunity costs such as time, monetary costs, and...
News
Isotretinoin benefits similar in overweight, obese adolescents, and those in normal weight range
However, the proportion of patients reporting headaches differed significantly between the groups.
News
Study spanning 2 decades offers insights into pediatric psoriasis trends
The researchers did not find that obesity was a marker of psoriasis severity in the cohort.
News
How well do JAK inhibitors work for atopic dermatitis?
“When you talk about how well they work, it really depends on what aspects of AD, what subgroups of AD, and how well they work with comorbidities...
News
Expert shares practical considerations when prescribing dupilumab
Real-world data suggests that the effectiveness of dupilumab is similar to the efficacy seen in clinical trials.
News
Baricitinib found effective for moderate to severe AD out to 52 weeks
At weeks 16, 32, and 52, the proportion of patients who achieved an EASI75 response was 40%, 51%, and 49%, respectively.
News
Ruxolitinib cream for atopic dermatitis found to be effective, safe up to 52 weeks
Treatment-related adverse events were reported in 5% of patients who applied 0.75% ruxolitinib cream and in 3% of patients who applied 1.5%...